ACA Improved Uninsurance Rates in COPD and Asthma, but Not Affordability
While the ACA effectively reversed coverage losses for patients with airway disease, neither care affordability nor disparities improved for these patients.
Asthma
Machine Learning Models Using EHR Data May Predict Asthma Exacerbation Risk
A novel machine learning algorithm using real-world outpatient data from electronic health records was capable of predicting asthma exacerbation risk.
Exercise-Induced Bronchoconstriction With or Without Asthma: A Unique Challenge
Patients with asthma who underwent exercise training have shown improvements in symptoms, pulmonary function, exercise capacity, and quality of life.
Lower Remission Rate in Asthma May Be Linked to Age at Diagnosis
Late-diagnosed asthma was identified as the most independent significant risk factor for non-remission in patients with asthma.
Maternal Asthma Rx Linked to Adverse Perinatal Outcomes
Prescription of asthma medications before and during pregnancy is associated with increased prevalence of adverse perinatal outcomes.
Tapering Oral Corticosteroids in Asthma: Expert Consensus Statements
Expert consensus statements regarding the use and tapering of oral corticosteroids may be used to help inform treatment in clinical practice and to optimize the management of patients with severe asthma.
Hormonal Contraceptives Linked to Decline in Asthma Exacerbation
Use of any and combined hormonal contraceptives is associated with a reduction in the risk for severe asthma exacerbation.
Severe, Poorly Controlled Pediatric Asthma Worsened by Allergen Sensitization
Children with severe or poorly controlled asthma with allergen sensitization have been shown to experience more asthma exacerbations and use more oral corticosteroids compared with those without allergen sensitization.
FDA Approvals That NPs, PAs Should Know
The FDA approved therapies to treat pain, type 2 diabetes, hormone deficiency, and juvenile idiopathic arthritis in September 2020.
New Indication: Trelegy Ellipta
Trelegy Ellipta is now approved for the maintenance treatment of asthma in patients aged 18 years and older. Learn more about this new indication with our slideshow, complete drug monograph, and downloadable PDF.
-
Loading...
-
Loading...
Next hm-slideshow in Uncategorized
